Invitae Hereditary Colorectal Cancer Guidelines-Based Panel
Use
The Invitae Hereditary Colorectal Cancer Guidelines-Based Panel includes genes associated with hereditary predisposition to colorectal polyps and colorectal cancer for which there are medically actionable, evidence-based management and risk-reduction options. It guides cancer screening and risk-reduction measures, potentially preventing cancer or leading to earlier diagnoses, thereby increasing the chances of successful treatment and survival. Genetic testing of these genes may aid in confirming a clinical diagnosis, predicting disease prognosis and progression, facilitating early detection, and informing family planning and genetic counseling.
Special Instructions
This test focuses on heritable germline mutations and is not suitable for detecting somatic mutations in tumor tissue. Customization of the test to include or exclude specific genes is possible prior to ordering.
Limitations
The test detects single nucleotide variants, insertions, deletions, and exon-level deletions/duplications with high sensitivity and specificity. However, In rare circumstances, certain single-exon copy number events might not be analyzed due to sequence properties or data quality issues. Likewise, structural rearrangements, mosaicism, and complex sequences like short tandem repeats may pose challenges. Promoter and non-coding sequence changes generally aren't addressed unless specified in some gene analyses.
New York Approved
Methodology
NGS (Targeted)
Biomarkers
Result Turnaround Time
10-21 days
Related Documents
For more information, please review the documents below
Specimen
Whole Blood
Volume
3mL
Minimum Volume
Not provided
Container
purple-top EDTA tube (K2EDTA or K3EDTA)
Other tests from different labs that may be relevant